ClinicalTrials.gg
CompletedNCT02785835GEHEP-002Updated Mar 16, 2022

Hepatocellular Carcinoma in HIV-infected Patients

An observational study in Hepatocellular Carcinoma, HIV and Chronic Hepatitis C, sponsored by Hospital Universitario de Valme. Completed at 30 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-16.

Sponsored by Hospital Universitario de Valme · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
477
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Carcinoma, Hepatocellular with a site in Spain — 24 open to participants now, 49 under way, 13 of them phase 3. Carcinoma, Hepatocellular · Spain.

Enrollment
9th of 21
477 · median 417
Started
2014
with 3 others
Observational
21 of 162
4 open now
Registered
61st of 162
by date

Among the 162 studies in Carcinoma, Hepatocellular with a site in Spain, this one is the 9th largest by enrollment of the 21 observational ones that give a count, is one of 4 that started in 2014, is one of 21 observational ones, and was the 61st registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

24 of the 162 studies in Carcinoma, Hepatocellular with a site in Spain are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Carcinoma, Hepatocellular with a site in Spain, or all of them as a file.
02

Study summary

Observational study. All HIV-infected patients who have been diagnosed of hepatocellular carcinoma (HCC), following the American Association for the Study of Liver Diseases (AASLD) criteria, in the participant centers are included. Epidemiological, clinical and laboratory data are collected. The clinical and epidemiological characteristics of HCC cases will be analyzed. The efficacy and outcomes after modalities of HCC therapy will be assessed. Mortality and its predictors will be also assessed. In those cases infected by hepatitis C virus (HCV), the impact of HCV therapy on outcomes will be analysed.

03

Conditions studied

  • Hepatocellular Carcinoma
  • HIV
  • Chronic Hepatitis C
  • Hepatitis B Virus
  • Liver Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

HIV-infected patients who are diagnosed of hepatocellular carcinoma following AASLD criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infection
  • Diagnosis of hepatocellular carcinoma according to American Association for the Study of Liver Diseases (AASLD) criteria

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
477 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Overall survival

    Overall survival after HCC diagnosis at 1 year

    Time frame: At 1 year

07

Study locations

30 sites
  • Hospital de Orihuela
    Orihuela, Alicante, Spain
  • Hospital Clínico Universitario de San Juan
    San Juan de Alicante, Alicante, Spain
  • Hospital Marina Baixa
    Villajoyosa, Alicante, Spain
  • Hospital German Trias i Pujol
    Badalona, Barcelona, Spain
  • Hospital General de Castellón
    Castellón De La Plana, Castellón, Spain
  • Hospital de La Linea
    La Línea de la Concepción, Cádiz, Spain
  • Hospital Universitario de Donostia
    San Sebastián, Guipúzcua, Spain
  • Hospital Universitario A Coruña
    A Coruna, La Coruña, Spain
  • Hospital de San Pedro
    Logroño, La Rioja, Spain
  • Hospital de Santa Lucía
    Cartagena, Murcia, Spain
  • Hospital Universitario de Canarias
    San Cristóbal de la Laguna, Santa Cruz De Tenerife, Spain
  • Hospital de San Eloy
    Barakaldo, Vizcaya, Spain
  • Hospital de Basurto
    Basurto, Vizcaya, Spain
  • Hospital de Cruces
    Bilbao, Vizcaya, Spain
  • Hospital de Galdakao
    Galdakao, Vizcaya, Spain
  • Hospital General Universitario de Alicante
    Alicante, Spain
  • Hospital de Puerto Real
    Cádiz, Spain
  • Hospital Universitario Reina Sofía
    Córdoba, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, Spain
  • Complejo Hospitalario de Huelva
    Huelva, Spain
  • Complejo Hospitalario de Jaén
    Jaén, Spain
  • Hospital Universitario La Princesa
    Madrid, Spain
  • Hospital Universitario Arrixaca
    Murcia, Spain
  • Hospital Regional Carlos Haya
    Málaga, Spain
  • Hospital Virgen de la Victoria
    Málaga, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41011, Spain
  • Hospital Clínico de Valencia
    Valencia, Spain
  • Hospital General de Valencia
    Valencia, Spain
  • Hospital Universitario y Politécnico La Fe
    Valencia, Spain
  • Hospital de Txagorritxu
    Vitoria, Álava, Spain
08

References and documents

Publications

  • Merchante N, Merino E, Rodriguez-Arrondo F, Tural C, Munoz J, Delgado-Fernandez M, Jover F, Galindo MJ, Rivero A, Lopez-Aldeguer J, Aguirrebengoa K, Romero-Palacios A, Martinez E, Pineda JA. HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. AIDS. 2014 Jan 2;28(1):41-7. doi: 10.1097/QAD.0000000000000005. PubMed 24056067 ↗
  • Merchante N, Merino E, Lopez-Aldeguer J, Jover F, Delgado-Fernandez M, Galindo MJ, Ortega E, Rivero A, Minguez C, Romero-Palacios A, Padilla S, Marquez-Solero M, Amador C, Rios-Villegas MJ, Tellez F, Portilla J, Pineda JA. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis. 2013 Jan;56(1):143-50. doi: 10.1093/cid/cis777. Epub 2012 Sep 5. PubMed 22955438 ↗
  • Merchante N, Ibarra S, Revollo B, Rodriguez-Arrondo F, Merino E, Delgado-Fernandez M, Montero-Alonso M, Tellez F, Galindo MJ, Rivero-Juarez A, Garcia MA, Minguez C, Romero-Palacios A, Garcia-Deltoro M, Pineda JA; GEHEP-002 Study Group. Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. AIDS. 2017 Jan 2;31(1):89-95. doi: 10.1097/QAD.0000000000001293. PubMed 27755109 ↗
  • Merchante N, Rodriguez-Arrondo F, Revollo B, Merino E, Ibarra S, Galindo MJ, Montero M, Garcia-Deltoro M, Rivero-Juarez A, Tellez F, Delgado-Fernandez M, Rios-Villegas MJ, Garcia MA, Vera-Mendez FJ, Ojeda-Burgos G, Lopez-Ruz MA, Metola L, Omar M, Aleman-Valls MR, Aguirrebengoa K, Portu J, Raffo M, Macias J, Pineda JA; GEHEP-002 Study Group. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. AIDS. 2018 Jul 17;32(11):1423-1430. doi: 10.1097/QAD.0000000000001809. PubMed 29596108 ↗
  • Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, Giannini EG, Brau N; Liver Cancer in HIV and ITA.LI.CA Study Groups. Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. J Clin Oncol. 2019 Feb 1;37(4):296-304. doi: 10.1200/JCO.18.00885. Epub 2018 Dec 18. PubMed 30562130 ↗
  • Merchante N, Figueruela B, Rodriguez-Fernandez M, Rodriguez-Arrondo F, Revollo B, Ibarra S, Galindo MJ, Merino E, Montero M, Tellez F, Garcia-Deltoro M, Rivero-Juarez A, Delgado-Fernandez M, Rios-Villegas MJ, Aguirrebengoa K, Garcia MA, Portu J, Vera-Mendez FJ, Villalobos M, Minguez C, De Los Santos I, Lopez-Ruz MA, Omar M, Galera C, Macias J, Pineda JA; GEHEP-002 Study Group. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. AIDS. 2019 Feb 1;33(2):269-278. doi: 10.1097/QAD.0000000000002065. PubMed 30325782 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Jun 2021 and a completion of Jun 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2016
First posted
May 30, 2016
Start
May 2014
Primary completionActual
Jun 30, 2021
CompletionActual
Jun 30, 2021
Last update
Mar 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02785835
Lead sponsor
Hospital Universitario de Valme
Responsible party
Nicolás Merchante (MD, PhD, Hospital Universitario de Valme) — Principal investigator
First posted
May 30, 2016
Start date
May 2014
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Last update
Mar 16, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion